sur VALBIOTIS (EPA:ALVAL)
VALBIOTIS launches Valbiotis®PRO for the prevention of metabolic diseases
Valbiotis is preparing to market Valbiotis®PRO Metabolic Health (Totum•63) in France, between February and March 2025. This dietary supplement targets the prevention of metabolic diseases, particularly type 2 diabetes. With 4 million diabetics and 2 to 3 million prediabetics in France, Valbiotis is targeting a major public health issue.
The product is based on the substance Totum•63, 100% plant-based and clinically validated. This innovation has been tested on 720 participants and benefits from 17 communications and 7 international publications. It has shown its effectiveness in reducing fasting blood sugar.
In line with the success of Valbiotis®PRO Cholesterol, distribution will be via pharmacies and an online channel. The products will be available with a recommended price starting at €22.95. The launch will involve a dedicated sales force to ensure promotion.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de VALBIOTIS